Blarcamesine

DB05592InvestigationalSmall molecule

Investigated for use/treatment in breast cancer.

Chemical structure of Blarcamesine
Primary indication
Investigated for use/treatment in breast cancer.Curator reviewed
Formula / weight
C19H23NO · 281.399 g/mol (avg)
Also known as
Anavex 2-73 · ANAVEX 2-73 FREE BASE · ANAVEX2-73 · ANAVEX2-73 free base · THD-DP-FM
Code names
AE-37

Resolves to

Compound
UNII9T210MMZ3FCAS195615-83-9ChEMBLCHEMBL4297224
Structure
InChIKeyBOTHKNZTGGXFEQ-UHFFFAOYSA-NSMILESCN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1
Targets
P11229CHRM1Q99720SIGMAR1

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Blarcamesine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In